December 8, 2020 – December 8, 2020 – FACIT congratulates Triphase Accelerator on interim results from its ongoing Phase 1 multi-center, open-label monotherapy study of TRPH-222.
December 1, 2020 – December 1, 2020 – FACIT is pleased to accept the invitation to join the national consortium as Lead Commercialization Advisor.
September 17, 2020 – September 17, 2020 – Since FACIT’s early seed investment in KA Imaging, the company has greatly expanded its IP portfolio, as well as the number of highly skilled jobs it has brought to Ontario.
June 26, 2020 – June 26, 2020 – FACIT congratulates Hamilton-based Fusion Pharma (NASDAQ: FUSN) on its initial public offering (IPO) with shares of the company beginning to trade on the Nasdaq Global Market exchange today.
Read More from FACIT congratulates Fusion Pharma on its Initial Public Offering
June 23, 2020 – June 23, 2020 – FACIT’s investments strategically address the seed-stage gap experienced by Ontario’s life sciences sector, fueling promising cancer breakthroughs towards a value inflection point and helping local start-ups establish and anchor jobs in the province.
June 9, 2020 – June 9, 2020 – FACIT’s award was specifically related to the 2019 historic US$1B partnership between its portfolio companies, Propellon Therapeutics and Triphase Accelerator, and US pharma giant Celgene (acquired by Bristol-Myers Squibb Company).
February 6, 2020 – February 6, 2020 – The output from this global study vastly improves the fundamental understanding of cancer and will provide guidance and new directions for its diagnosis and treatment
February 5, 2020 – February 5, 2020 – The winning pitch was delivered by Mr. Meir Dick of Bridge7 Oncology. This local start-up is scaling clinical expertise with AI to automate and improve the efficiency, consistency and quality of delivering cancer care.
February 4, 2020 – “Commercializing innovation for cancer patients and economic impact”, February 4, 2020
January 28, 2020 – January 28, 2020 – Spun out of the University of Toronto, both start-ups have previously received funding through FACIT’s proof-of-concept Prospects Fund.